Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2

被引:40
作者
Vokurka, S. [1 ]
Steinerova, K. [1 ]
Karas, M. [1 ]
Koza, V. [1 ]
机构
[1] Univ Hosp Plzen Pilsen, Dept Haematooncol, Plzen 30460, Pilsen, Czech Republic
关键词
oral mucositis; melphalan; stem cell transplantation; toxicity; graft-versus-host disease; VERSUS-HOST-DISEASE; HIGH-DOSE MELPHALAN; MARROW-TRANSPLANTATION; CHEMOTHERAPY; FLUDARABINE; PREVENTION; RECIPIENTS; THERAPY; MYELOMA;
D O I
10.1038/bmt.2009.66
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The fludarabine ( FLU)/melphalan (MEL) conditioning regimen containing FLU and high-dose MEL was analyzed in comparison with the BU/CY2 regimen to characterize oral mucositis ( OM) and risk factors. OM incidence significantly varied between BU/CY2 and FLU/ MEL ( 100 vs 78%, P = 0.004), but the incidence of severe OM grades 3-4 WHO and kinetics of OM were fully comparable. Patients with OM persisting on day +21 had more acute GVHD (68 vs 32%, P = 0.005), which tended to occur earlier than among those without such prolonged OM. Multivariate analysis showed significant dependency of acute GVHD on severity and prolonged duration of OM and significant correlation between OM severity and its prolonged duration. Body surface area-based dosing in the FLU/ MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2.5-5.2 mg/kg, median 3.5). In multivariate analysis, MEL dose per kilogram of body weight was found to be a significant predictor of OM incidence and severity. Female gender and lower body mass index were less important variables than the fact that the actual dose of MEL administered per kilogram of body weight was relatively high when the dosage was calculated on the basis of body surface area. Bone Marrow Transplantation ( 2009) 44, 601-605; doi: 10.1038/bmt.2009.66; published online 6 April 2009
引用
收藏
页码:601 / 605
页数:5
相关论文
共 50 条
  • [31] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients
    M Iravani
    M R Evazi
    S A Mousavi
    A R Shamshiri
    M Tavakoli
    A Ashouri
    S Samiee
    B Chahardovali
    K Alimoghaddam
    S H Ghaffari
    A Ghavamzadeh
    Bone Marrow Transplantation, 2007, 40 : 105 - 110
  • [32] A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen
    Satwani, Prakash
    Bhatia, Monica
    Garvin, James H., Jr.
    George, Diane
    Dela Cruz, Filemon
    Le Gall, John
    Jin, Zhezhen
    Schwartz, Joseph
    Duffy, Deirdre
    van de Ven, Carmella
    Foley, Sandra
    Hawks, Rio
    Morris, Erin
    Baxter-Lowe, Lee Ann
    Cairo, Mitchell S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : 324 - 329
  • [33] Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit
    Mokart, Djamel
    Granata, Angela
    Crocchiolo, Roberto
    Sannini, Antoine
    Chow-Chine, Laurent
    Brun, Jean-Paul
    Bisbal, Magali
    Faucher, Marion
    Faucher, Catherine
    Blache, Jean-Louis
    Castagna, Luca
    Fuerst, Sabine
    Blaise, Didier
    JOURNAL OF CRITICAL CARE, 2015, 30 (05) : 1107 - 1113
  • [34] Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
    Hannon, Muriel
    Beguin, Yves
    Ehx, Gregory
    Servais, Sophie
    Seidel, Laurence
    Graux, Carlos
    Maertens, Johan
    Kerre, Tessa
    Daulne, Coline
    de Bock, Muriel
    Fillet, Marianne
    Ory, Aurelie
    Willems, Evelyne
    Gothot, Andre
    Humblet-Baron, Stephanie
    Baron, Frederic
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3131 - 3139
  • [35] Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen
    Saure, Christian
    Schroeder, Thomas
    Zohren, Fabian
    Groten, Anke
    Bruns, Ingmar
    Czibere, Akos
    Galonska, Lars
    Kondakci, Mustafa
    Weigelt, Christian
    Fenk, Roland
    Germing, Ulrich
    Haas, Rainer
    Kobbe, Guido
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) : 466 - 472
  • [36] HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen
    Kroeger, Nicolaus
    Zabelina, Tatjana
    Binder, Thomas
    Ayuk, Francis
    Bacher, Ulrike
    Amtsfeld, Gitta
    Lellek, Heinrich
    Schrum, Johanna
    Erttmann, Rolf
    Eiermann, Thomas
    Zander, Axel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (04) : 454 - 462
  • [37] Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation
    Akahoshi, Yu
    Kanda, Junya
    Gomyo, Ayumi
    Hayakawa, Jin
    Komiya, Yusuke
    Harada, Naonori
    Kameda, Kazuaki
    Ugai, Tomotaka
    Wada, Hidenori
    Ishihara, Yuko
    Kawamura, Koji
    Sakamoto, Kana
    Sato, Miki
    Terasako-Saito, Kiriko
    Kimura, Shun-ichi
    Kikuchi, Misato
    Nakasone, Hideki
    Kako, Shinichi
    Kanda, Yoshinobu
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (09) : 1678 - 1683
  • [38] Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation
    Wu, Jin
    Fu, Hai-Xia
    He, Yun
    Mo, Xiao-Dong
    Liu, Xiao
    Cai, Xuan
    Gui, Ruo-Yun
    Liu, Hui-Xin
    Yan, Chen-Hua
    Chen, Yu-Hong
    Chang, Ying-Jun
    Xu, Lan-Ping
    Liu, Kai-Yan
    Huang, Xiao-Jun
    Zhang, Xiao-Hui
    BONE MARROW TRANSPLANTATION, 2021, 56 (09) : 2097 - 2107
  • [39] Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
    Ljungman, Per
    Perez-Bercoff, Lena
    Jonsson, Jerker
    Avetisyan, Gayane
    Sparrelid, Elda
    Aschan, Johan
    Barkholt, Lisbeth
    Larsson, Kajsa
    Winiarski, Jacek
    Yun, Zhibing
    Ringden, Olle
    HAEMATOLOGICA, 2006, 91 (01) : 78 - 83
  • [40] Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation
    Kubo, Hiroyuki
    Imataki, Osamu
    Fukumoto, Tetsuya
    Oku, Maki
    Ishida, Tomoya
    Kubo, Yukiko Hamasaki
    Kida, Jun-ichiro
    Uemura, Makiko
    Fujita, Haruyuki
    Ohno, Hirofumi
    Ide, Makoto
    Ohnishi, Hiroaki
    Kadowaki, Norimitsu
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11): : 949.e1 - 949.e8